Warning: I lost quite a few dollars investing in VVUS, which tanked in a major way after its flagship obesity drug was approved.
If after 2 quarters on the market the recently approved drug is not growing revenues, I'm jumping ship. I'm assuming that the Drug will need approval for Medicare reimbursement and will have to find its way onto the forumlaries to insurers.
AND, the company will continue to have R&D expenses.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.